Crispr Therapeutics shares tumble after significant earnings miss
Investing.com - JMP Securities has reiterated its Market Outperform rating and $22.00 price target on Acres Commercial Realty Corp (NYSE:ACR) following the company’s second-quarter 2025 results released on July 30. The stock has shown strong momentum, delivering a 21.86% return year-to-date, with InvestingPro data indicating the company is currently undervalued.
The price target represents potential upside of approximately 15% from current levels and values the company at 0.79 times current book value, according to JMP Securities. This aligns with the company’s current price-to-book ratio of 0.31x, which is notably low according to InvestingPro analysis.
Acres Commercial Realty reported a GAAP loss of $0.10 per share and earnings available for distribution (EAD) of $0.04 per share for the second quarter. The GAAP results included a $780,000, or $0.11 per share, reversal of CECL reserves due to improving fundamentals in the loan portfolio.
The company’s GAAP book value decreased 2.0% to $27.93 per share from $28.50 at March 31. During the quarter, ACR repurchased $5.1 million of its common stock, which increased book value by $0.38 per share.
The company hosted its earnings conference call on Thursday, July 31, with a replay available via dial-in.
In other recent news, Acres Commercial Realty Corp reported its second-quarter 2025 earnings, which revealed a notable miss on earnings per share (EPS) compared to market expectations. The company posted an EPS of -$0.10, significantly below the forecasted $0.18, resulting in a negative surprise of 155.56%. Despite the earnings miss, the stock price remained relatively stable. These developments highlight the company’s recent financial performance challenges. Investors may want to keep an eye on any further updates regarding Acres Commercial Realty’s financial strategies and market reactions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.